- Home
- DXC vs VKTX Comparison
DXC vs VKTX Comparison
Compare DXC & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXC
- VKTX
- Stock Information
- Founded
- DXC 1959
- VKTX 2012
- Country
- DXC United States
- VKTX United States
- Employees
- DXC N/A
- VKTX N/A
- Industry
- DXC EDP Services
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- DXC Technology
- VKTX Health Care
- Exchange
- DXC Nasdaq
- VKTX Nasdaq
- Market Cap
- DXC 3.3B
- VKTX 3.4B
- IPO Year
- DXC N/A
- VKTX 2015
- Fundamental
- Price
- DXC $17.06
- VKTX $25.65
- Analyst Decision
- DXC Hold
- VKTX Strong Buy
- Analyst Count
- DXC 7
- VKTX 11
- Target Price
- DXC $21.29
- VKTX $95.18
- AVG Volume (30 Days)
- DXC 2.9M
- VKTX 4.0M
- Earning Date
- DXC 05-15-2025
- VKTX 04-23-2025
- Dividend Yield
- DXC N/A
- VKTX N/A
- EPS Growth
- DXC N/A
- VKTX N/A
- EPS
- DXC N/A
- VKTX N/A
- Revenue
- DXC $13,088,000,000.00
- VKTX N/A
- Revenue This Year
- DXC N/A
- VKTX N/A
- Revenue Next Year
- DXC N/A
- VKTX N/A
- P/E Ratio
- DXC N/A
- VKTX N/A
- Revenue Growth
- DXC N/A
- VKTX N/A
- 52 Week Low
- DXC $14.79
- VKTX $24.41
- 52 Week High
- DXC $24.83
- VKTX $82.00
- Technical
- Relative Strength Index (RSI)
- DXC 39.93
- VKTX 37.65
- Support Level
- DXC $16.19
- VKTX $25.80
- Resistance Level
- DXC $17.57
- VKTX $29.60
- Average True Range (ATR)
- DXC 0.56
- VKTX 1.69
- MACD
- DXC 0.11
- VKTX -0.17
- Stochastic Oscillator
- DXC 48.88
- VKTX 17.19
About DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.